Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00191256 · ClinicalTrials.gov registry record · Phase 2
Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
NCT00191256 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 77 participants.
The verdict
NCT00191256, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
Study Summary
To evaluate the rate of complete pathological response after 3 cycles of gemcitabine containing chemotherapy.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2001-06 |
| Est. Completion | 2006-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00191256
The ClinicalTrials.gov registry entry for NCT00191256 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT00191256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00191256 about?
NCT00191256 is a clinical study titled "Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer". To evaluate the rate of complete pathological response after 3 cycles of gemcitabine containing chemotherapy.
What is the current status of trial NCT00191256?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2001-06. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00191256?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00191256?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.